Compound Evidence File
#EC-2026-0162
Nandrolone Phenylpropionate (NPP) Raw
Filed under Raw Materials. The bureau holds 109 laboratory returns for this compound from 35 distinct subjects. Scores below are per-subject aggregates; open a subject row for the underlying evidence.
Cross-Index
Subjects Shipping This Compound
35 SUBJECTS| Subject | Grade | Samples | Mean | Min | Max | First seen | Last seen |
|---|---|---|---|---|---|---|---|
| Tianjin Finder Chemical TFCCASE #VI-2026-0693 | A | 7 | 10.0 | 9.9 | 10.0 | 14 Nov 2025 | 16 Apr 2026 |
| HomopeptideCASE #VI-2026-0760 | A | 5 | 10.0 | 9.9 | 10.0 | 23 May 2026 | 23 May 2026 |
| Shanghai ERP BiotechnologyCASE #VI-2026-0936 | A | 4 | 10.0 | 9.9 | 10.0 | 9 Nov 2025 | 27 Mar 2026 |
| BachemCASE #VI-2026-0314 | A | 4 | 10.0 | 10.0 | 10.0 | 1 Dec 2025 | 1 Jun 2026 |
| GenScript PeptidesCASE #VI-2026-0860 | A | 4 | 10.0 | 9.9 | 10.0 | 12 Apr 2026 | 12 Jul 2026 |
| Sangon BioCASE #VI-2026-0671 | A | 3 | 10.0 | 10.0 | 10.0 | 12 Nov 2025 | 24 Jun 2026 |
| QYAOBIOCASE #VI-2026-0861 | A | 3 | 10.0 | 9.9 | 10.0 | 2 Jan 2026 | 14 May 2026 |
| Hybio PharmaceuticalCASE #VI-2026-0065 | A | 3 | 10.0 | 10.0 | 10.0 | 11 Dec 2025 | 21 Jun 2026 |
| SinoPepCASE #VI-2026-0387 | A | 3 | 10.0 | 9.9 | 10.0 | 18 Jun 2026 | 5 Aug 2026 |
| Peptide TechnologiesCASE #VI-2026-0694 | X | 1 | 10.0 | 10.0 | 10.0 | 3 Jun 2025 | 3 Jun 2025 |
| WuXi TIDESCASE #VI-2026-0335 | A | 4 | 9.9 | 9.9 | 10.0 | 23 Mar 2026 | 4 Jun 2026 |
| AmbioPharmCASE #VI-2026-0177 | A | 4 | 9.9 | 9.9 | 10.0 | 10 Jan 2026 | 15 Jun 2026 |
| JEEP PeptidesCASE #VI-2026-0457 | A | 3 | 9.9 | 9.9 | 10.0 | 25 May 2026 | 13 Jun 2026 |
| Kerui PeptidesCASE #VI-2026-0626 | A | 3 | 9.9 | 9.9 | 10.0 | 4 Jan 2026 | 2 Jun 2026 |
| Sigma-AldrichCASE #VI-2026-0829 | A | 3 | 9.9 | 9.9 | 9.9 | 15 Dec 2025 | 9 May 2026 |
| Hubei JianxiangCASE #VI-2026-0048 | A | 2 | 9.9 | 9.9 | 10.0 | 1 Jan 2026 | 9 Jul 2026 |
| Mokemei BiotechnologyCASE #VI-2026-0540 | A | 2 | 9.9 | 9.9 | 10.0 | 4 May 2026 | 16 Jun 2026 |
| Flourishglobal PeptideCASE #VI-2026-0630 | A | 2 | 9.9 | 9.9 | 10.0 | 9 Apr 2026 | 8 May 2026 |
| Shanghai Wibson BiotechnologyCASE #VI-2026-0379 | A | 2 | 9.9 | 9.9 | 10.0 | 14 Nov 2025 | 12 Jul 2026 |
| Chinese Peptide CompanyCASE #VI-2026-0184 | A | 2 | 9.9 | 9.9 | 10.0 | 17 May 2026 | 26 Jun 2026 |
| Shanghai Sigma AudleyCASE #VI-2026-0505 | A | 2 | 9.9 | 9.9 | 9.9 | 16 Dec 2025 | 14 Apr 2026 |
| PolyPeptide GroupCASE #VI-2026-0143 | A | 2 | 9.9 | 9.9 | 10.0 | 17 Apr 2026 | 1 Aug 2026 |
| Thermo Fisher ScientificCASE #VI-2026-0142 | A | 2 | 9.9 | 9.9 | 9.9 | 27 Apr 2026 | 22 Jul 2026 |
| AsymchemCASE #VI-2026-0091 | A | 2 | 9.9 | 9.9 | 10.0 | 4 Mar 2026 | 15 Apr 2026 |
| Paradigm PeptideCASE #VI-2026-0759 | X | 1 | 9.9 | 9.9 | 9.9 | 11 Jun 2025 | 11 Jun 2025 |
| Wuhan Wansheng Bio (WWB)CASE #VI-2026-0594 | A | 7 | 9.1 | 8.6 | 10.0 | 23 May 2026 | 23 May 2026 |
| CellupepCASE #VI-2026-0888 | X | 1 | 9.0 | 9.0 | 9.0 | 3 Jul 2025 | 3 Jul 2025 |
| Shanghai Sigma Audley SSACASE #VI-2026-0486 | A | 4 | 8.8 | 7.3 | 10.0 | 24 May 2026 | 24 May 2026 |
| Nantong Guangyuan Chemical GYCCASE #VI-2026-0284 | A | 4 | 8.4 | 7.7 | 8.8 | 23 May 2026 | 23 May 2026 |
| Glbiochem (Shanghai)CASE #VI-2026-0704 | A | 2 | 8.3 | 6.7 | 10.0 | 24 May 2026 | 24 May 2026 |
| Skye PeptidesCASE #VI-2026-0451 | X | 3 | 8.3 | 6.8 | 9.6 | 24 Apr 2025 | 24 May 2026 |
| Qingdao Sigma Chemical QSCCASE #VI-2026-0538 | A | 3 | 8.0 | 7.5 | 8.5 | 21 May 2026 | 21 May 2026 |
| Tianjin Ruiwang New Material Technology CoCASE #VI-2026-0192 | X | 10 | 7.0 | 4.7 | 9.1 | 16 Mar 2025 | 17 May 2026 |
| Chimera PeptidesCASE #VI-2026-0260 | X | 1 | 6.6 | 6.6 | 6.6 | 24 Apr 2025 | 24 Apr 2025 |
| ZZQ PeptidesCASE #VI-2026-0550 | X | 1 | 3.9 | 3.9 | 3.9 | 3 Jul 2025 | 3 Jul 2025 |
Open any subject to view the batch-level evidence for Nandrolone Phenylpropionate (NPP) Raw alone.